Kessels et al.,2626 Kessels H, Beguin S, Andree H, Hemker HC. Measurement of thrombin generation in whole blood - the effect of heparin and aspirin. Thromb Haemost. 1994;72(1):78-83. Arachchillage et al.2727 Arachchillage DR, Efthymiou M, Mackie IJ, Lawrie AS, Machin SJ, Cohen H. Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism. Thromb Res. 2015;135(2):388-93. and Zabczyk et al.2828 Ząbczyk M, Majewski J, Karkowski G, Malinowski KP, Undas A. Vitamin K antagonists favourably modulate fibrin clot properties in patients with atrial fibrillation as early as after 3 days of treatment: relation to coagulation factors and thrombin generation. Thromb Res. 2015;136(4):832-8.
|
To monitor treatment with oral anticoagulants and antiplatelet drugs. |
Al Dieri et al.2929 Al Dieri R, Peyvandi F, Santagostino E, Giansily M, Mannucci PM, Schved JF, et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost. 2002;88(4):576-82.
|
To assess bleeding risk in patients with von Willebrand disease. |
Simioni et al.,3030 Simioni P, Castoldi E, Lunghi B, Tormene D, Rosing J, Bernardi F. An underestimated combination of opposites resulting in enhanced thrombotic tendency. Blood. 2005;106(7):2363-5. Castoldi et al.,3131 Castoldi E, Simioni P, Tormene D, Thomassen MC, Spiezia L, Gavasso S, et al. Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia. J Thromb Haemost. 2007;5(5):971-9. Alhenc-Gelas et al.3232 Alhenc-Gelas M, Canonico M, Picard V. Influence of natural SERPINC1 mutations on ex vivo thrombin generation. J Thromb Haemost. 2010;8(4):845-8. and Castoldi at al.3333 Castoldi E, Maurissen LF, Tormene D, Spiezia L, Gavasso S, Radu C, et al. Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency. Haematologica. 2010;95(9):1563-71.
|
To evaluate hypercoagulable states in patients with the prothrombin G20210A mutation, factor V Leiden, and antithrombin or protein S deficiency. |
Tripodi et al.3434 Tripodi A, Martinelli I, Chantarangkul V, Battaglioli T, Clerici M, Mannucci PM. The endogenous thrombin potential and the risk of venous thromboembolism. Thromb Res. 2007;121(3):353-9. and Hron et al.3535 Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA. 2006;296(4):397-402.
|
To use the thrombin generation test to predict the recurrence of venous thromboembolism. |
Lewis et al.3636 Lewis SJ, Stephens E, Florou G, Macartney NJ, Hathaway LS, Knipping J, et al. Measurement of global haemostasis in severe haemophilia: a following factor VIII infusion. Br J Haematol. 2007;138(6):775-82. and Matsumoto et al.3737 Matsumoto T, Shima M, Takeyama M, Yoshida K, Tanaka I, Sakurai Y, et al. The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay. J Thromb Haemost. 2006;4(2):377-84.
|
To estimate bleeding risk in patients with hemophilia using factor VIII or factor VIIa. |
van Hylckama et al.3838 van Hylckama VA, Christiansen SC, Luddington R, Cannegieter SC, Rosendaal FR, Baglin TP. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol. 2007;138(6):769-74.
|
To assess risk of deep venous thrombosis. |
Brummel-Ziedins et al.3939 Brummel-Ziedins K, Undas A, Orfeo T, Gissel M, Butenas S, Zmudka K, et al. Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition. J Thromb Haemost. 2008;6(1):104-10.
|
To discriminate between acute and stable coronary artery disease. |
Segers et al.4040 Segers O, van Oerle RV, ten Cate HT, Rosing J, Castoldi E. Thrombin generation as an intermediate phenotype for venous thrombosis. Thromb Haemost. 2010;103(1):114-22.
|
To use the thrombin generation test to identify novel genetic risk factors for venous thromboembolism. |
Carcaillon et al.4141 Carcaillon L, Alhenc-Gelas M, Bejot Y, Spaft C, Ducimetière P, Ritchie K, et al. Increased thrombin generation is associated with acute ischemic stroke but not with coronary heart disease in the elderly: the Three-City cohort study. Arterioscler Thromb Vasc Biol. 2011;31(6):1445-51.
|
To correlate thrombin generation with coronary heart disease and acute ischemic stroke in the elderly. |
Tchaikovski et al.4242 Tchaikovski SN, Thomassen MC, Costa SD, Peeters LL, Rosing J. Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia. Thromb Haemost. 2011;106(5):914-21.
|
To investigate changes and determinants of thrombin generation and activated protein C resistance in the first 16 weeks of gestation in women with a history of preeclampsia. |
Bosch et al.4343 Bosch Y, Al Dieri R, ten Cate H, Nelemans P, Bloemen S, Hemker C, et al. Preoperative thrombin generation is predictive for the risk of blood loss after cardiac surgery: a research article. J Cardiothorac Surg. 2013;8:154.
|
To evaluate patients undergoing cardiac surgery. |
Orsi et al.4444 Orsi FA, Angerami RN, Mazetto BM, Quaino SK, Santiago-Bassora F, Castro V, et al. Reduced thrombin formation and excessive fibrinolysis are associated with bleeding complications in patients with dengue fever: a case-control study comparing dengue fever patients with and without bleeding manifestations. BMC Infect Dis. 2013;13:350.
|
To evaluate possible pathophysiological mechanisms that may contribute to the bleeding tendency observed in patients with dengue fever. |
Kamphuisen et al.4545 Kamphuisen PW, ten Cate H. Cardiovascular risk in patients with hemophilia. Blood. 2014;123(9):1297-301.
|
To evaluate cardiovascular risk in patients with hemophilia. |
Gould et al.4646 Gould TJ, Vu TT, Swystun LL, Dwivedi DJ, Mai SH, Weitz JI, et al. Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. Arterioscler Thromb Vasc Biol. 2014;34(9):1977-84.
|
To assess procoagulant potential of intact neutrophil extracellular traps released from activated neutrophils. |
Picoli-Quaino et al.4747 Picoli-Quaino SK, Alves BE, Faiotto VB, Montalvao SA, De Souza CA, Annichino-Bizzacchi JM, et al. Impairment of thrombin generation in the early phases of the host response of sepsis. J Crit Care. 2014;29(1):31-6.
|
To investigate hypercoagulability during the very early phases of the host response to an infection over the clinical course of sepsis and septic shock. |
Loeffen et al.4848 Loeffen R, Godschalk TC, van Oerle R, Spronk HM, Hackeng CM, ten Berg JM, et al. The hypercoagulable profile of patients with stent thrombosis. Heart. 2015;101(14):1126-32.
|
To evaluate the hypercoagulable profile of patients with stent thrombosis. |
Zia et al.4949 Zia A, Callaghan MU, Callaghan JH, Sawni A, Bartlett H, Backos A, et al. Hypercoagulability in adolescent girls on oral contraceptives - global coagulation profile and estrogen receptor polymorphisms. Am J Hematol. 2015;90(8):725-31. and Glintborg et al.5050 Glintborg D, Sidelmann JJ, Altinok ML, Mumm H, Andersen M. Increased thrombin generation in women with polycystic ovary syndrome: a pilot study on the effect of metformin and oral contraceptives. Metabolism. 2015;64(10):1272-8.
|
To evaluate hypercoagulability in women using oral contraceptives. |
Dargaud et al.5151 Dargaud Y, Scoazec JY, Wielders SJ, Trzeciak C, Hackeng TM, Négrier C, et al. Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation. Blood. 2015;125(9):1497-501.
|
To identify an autosomal dominant bleeding disorder in a family, caused by a thrombomodulin mutation. |
Barco et al.5252 Barco S, Whitney Cheung Y, Coppens M, Hutten BA, Meijers JC, Middeldorp S. In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate. Br J Haematol. 2016;172(2):255-61. and Honickel et al.5353 Honickel M, Maron B, van Ryn J, Braunschweig T, ten Cate H, Spronk HM, et al. Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model. Thromb Haemost. 2016;115(2):271-84.
|
To evaluate the effect of prothrombin complex concentrate in reversing the anticoagulant effect of rivaroxaban and dabigatran. |